Case study

SGA Helped a Leading Pharmaceutical Innovator to Understand the Disease Landscape for a Rare Indication in the US

Healthcare Case Study Helped a Leading Pharmaceutical

BUSINESS SITUATION

The client, a prominent pharmaceutical innovator, had a drug in the pre-clinical stage for a rare non-oncology disease, Hereditary Angioedema (HAE). The company wanted to understand disease pathophysiology, epidemiology, the competitive landscape, and the unmet needs in disease treatment and prophylaxis.

SGA APPROACH

  • SGA gathered information from a diverse range of sources, including paid databases and publicly available resources, such as company press releases, financial documents, investor presentations, and corporate reports.
  • A comprehensive study was conducted to gain insights into the treatment algorithm, the US FDA-approved on-demand and prophylaxis therapies, and their respective market shares. SGA also explored off-label usage trends.
  • To establish a competitive clinical pipeline, SGA performed extensive secondary research by utilizing various clinical trial registries, company pipeline data, publications, and SEC filings.
  • SGA conducted a publication analysis study to understand the current therapeutic targets, advancements in therapies, biomarker research, and potential novel targets.
  • SGA analyzed the unmet needs in the field, assessing the rationale for developing new therapies for HAE and identifying opportunities and challenges within the HAE space.

ENGAGEMENT

SGA engaged with the Head of Competitive Intelligence & Commercial insights and analytics of a pharmaceutical company based in the US. SGA actively collaborated with the client throughout the entire process.

BENEFITS & OUTCOME

Utilizing SGA insights, the client managed to refine its commercial strategy, enhancing competitiveness in the marketplace

KEY TAKEAWAYS

  • HAE is a genetic condition causing painful and pronounced swelling in various parts of the body
  • The early-stage pipeline primarily consists of oral medications, while the late-stage is more oriented toward injectable drugs
  • Approved therapies are primarily injected/infused, with a high unmet need for efficacious oral administration
  • The treatment aims to minimize lifestyle compromises, yet attacks continue to induce anxiety and adversely affect one’s quality of life

We bring comprehensive data driven insights to everyone, everywhere

In depth-analysis with simple solutions